Kazia Therapeutics Limited ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-15.2%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.01next fiscal year
Monitoring Framework
Key Performance Indicators
Paxalisib Phase 1b TNBC Trial Enrollment Quarterly12.0
Cash and Cash Equivalents (USD) Quarterly46MTarget: Maintain sufficient runway into 2029
Watch Items
- Nasdaq Minimum Value of Listed Securities (MVLS) ComplianceTrigger: Failure to maintain MVLS of $35 million or request/win a Hearings Panel appealAction: Monitor SEC filings for Nasdaq Hearings Panel decisions and potential delisting/suspension notices.
- Paxalisib Glioblastoma (GBM) Regulatory PathwayTrigger: FDA feedback on the design and execution of a pivotal registrational studyAction: Review corporate updates regarding the final protocol and initiation of the registrational study.
- Preclinical IND-Enabling Studies for NDL2 and MSETCTrigger: Initiation of IND-enabling studies in 2026Action: Track progress of the first-in-class nuclear PD-L1 degrader (NDL2) and SETDB1 inhibitor (MSETC) platforms.
Research as of 19 Jun 2026